Research library

Key finding

Reviewing more than 100 papers, the authors describe preclinical anticancer activity for Melittin nanocarriers across multiple tumour models, alongside delivery strategies intended to reduce off-target and haemolytic effects.

Key finding

Melittin disrupted EGFR and HER2 activation in breast-cancer cells, and its addition enhanced docetaxel-associated tumour suppression in a mouse allograft model.

Key finding

Melittin showed antibacterial activity against MRSA in laboratory testing and improved survival or wound recovery in two MRSA-infected mouse models.

Key finding

Melittin-loaded nanoparticles reduced infectivity of two HIV-1 strains in cell assays while preserving the viability of the vaginal epithelial cells tested.

Key finding

MnO2-Melittin nanoparticles produced stronger immune activation and greater inhibition of tumour growth and lung metastasis than either component alone across several mouse tumour models.

Key finding

The study reports that mLT-Gel@HC-EA treatment restored Th17/Treg-mediated immunity balance, reduced inflammatory factor release (TNF-α, IL-6, IL-1β), and alleviated inflammation at the lesion site.

Key finding

The study reports that immunotherapy is a rapidly developing and effective strategy for cancer therapy.

Key finding

The study reports that 5 microg of melittin is sufficient to produce pain in humans and 10% lidocaine gel differentially decreases the melittin-induced axon reflex without any significant analgesic effect.

Key finding

The study reports that these advancements hold promise for the creation of innovative and enhanced therapeutic approaches based on MLT for the treatment of cancer.

Key finding

The study reports that melittin can effectively enhance the therapeutic properties of some first-line drugs.

Key finding

The study reports that however, the clinical application of melittin is restricted due to its severe hemolytic activity.

Key finding

The study reports that hence, there is a dire need for discovery of novel anti-fungal agents.

Key finding

The study reports that in this respect, animal venoms represent a rich repertoire of pharmacologically active components.

Key finding

The study reports that the general health status and the clinical scores for conjunctivitis and stomatitis improved in cats treated with melittin.

Key finding

The study reports that from the range of molecules tested, the majority of effective AMPs were derived from bee/wasp venoms.

Key finding

The study reports that through pyroptosis mediated by caspase-1-GSDMD and caspase-3-GSDME axes synchronically, low-dosage apatinib and melittin could synergistically achieve a comparable therapeutic potential with reduced AEs.